Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;7(12):e2451013.
doi: 10.1001/jamanetworkopen.2024.51013.

Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use

Yeliz Bulut  1   2 , Jon Jarløv Rasmussen  1 , Niels Brandt-Jacobsen  1   3 , Jan Frystyk  4   5 , Mario Thevis  6 , Morten Schou  2   7 , Finn Gustafsson  2   8 , Philip Hasbak  3 , Caroline Kistorp  1   2
Affiliations

Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use

Yeliz Bulut et al. JAMA Netw Open. .

Abstract

Importance: Long-term use of anabolic androgenic steroids (AASs) is associated with a high risk of left ventricular hypertrophy, heart failure with reduced systolic function, and early sudden death, with the mechanism of progression being understudied. Early and persistent impaired myocardial microcirculation could be of clinical importance and a potential underlying mechanism of frequent and early cardiac disease among individuals with AAS use and a future potential target for intervention.

Objective: To investigate coronary microcirculation by measuring myocardial flow reserve (MFR) in men with current and former AAS use compared with controls with no prior AAS use, using cardiac rubidium 82 (82Rb) positron emission tomography/computed tomography (PET/CT).

Design, setting, and participants: This cross-sectional study included men involved in recreational strength training without established cardiovascular disease grouped according to their history of AAS use. The study was conducted November 24, 2021, to August 16, 2023.

Exposure: Cardiac PET/CT with 82Rb was performed at rest and after adenosine-induced stress.

Main outcome and measure: The primary outcome of this study was the MFR among the study groups; a secondary outcome was the coronary calcium score. By definition, impaired myocardial microcirculation was determined using a cutoff of MFR less than 2, and subclinically impaired microcirculation was determined using a cutoff of MFR less than 2.5.

Results: A total of 90 men (32 with current AAS use, 31 with former AAS use, and 27 controls) were included. Mean (SD) age was 35.1 (8.7) years. Elapsed duration since AAS cessation was a geometric mean of 1.5 (95% CI, 0.9-2.5) years. Eighteen men (58.1%) with former use discontinued AAS use more than 1 year before enrollment. Impaired MFR was present in those with current (6 [18.8%]) and former (1 [3.2%]) use, whereas no impairment was observed among the controls (P = .02). Subclinically impaired MFR was higher among men with current (9 [28.1%]) and former (8 [25.8%]) AAS use than the controls (1 [3.7%]) (P = .02). In a multivariable logistic regression model among men with former AAS use, every doubling of the accumulated weekly duration of AAS use (log2) was independently associated with a factor 2 increase in the risk of impaired MFR less than 2.5 (odds ratio, 2.1; 95% CI, 1.03-4.35; P = .04).

Conclusions and relevance: In this study, men with former AAS use displayed impaired MFR years after AAS cessation, suggesting impaired coronary microcirculation persists beyond active use.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Frystyk reported receiving grants from Novo Nordisk Foundation during the conduct of the study. Dr Schou reported receiving lecture fees from Bohringer, Novo, Novartis, and AstraZeneca outside the submitted work. Dr Gustafsson reported receiving personal fees from Abbott, Pfizer, Bayer, AstraZeneca, Alnylam, Ionis, and Novartis outside the submitted work. Dr Kistorp reported receiving grants from Novo Nordisk Foundation during the conduct of the study and personal fees from Sanofi Genzyme, Amicus, Chiesi, and Boehringer Ingelheim outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Prevalence of Impaired Myocardial Flow Reserve and Subclinically Impaired Myocardial Flow Reserve
Prevalence of impaired MFR (<2.0; A) and subclinically impaired MFR (<2.5; B) among the 3 study groups. Error bars indicate 95% CIs. Overall P = .02 from Fisher exact test. Pairwise comparisons for P values shown. AAS indicates androgenic anabolic steroid; MFR, myocardial flow reserve.
Figure 2.
Figure 2.. Multivariable Logistic Regression Analyses on 31 Individuals With Former Androgenic Anabolic Steroid (AAS) Use Using Myocardial Flow Reserve Less Than 2.5 as the Dependent Variable
See this image and copyright information in PMC

References

    1. Pope HG, Kanayama G. Reduced quality of life in former androgen users: an evolving public-health concern. J Clin Endocrinol Metab. 2023;00:1-2. doi:10.1210/clinem/dgad661 - DOI - PubMed
    1. Pope HG Jr, Khalsa JH, Bhasin S. Body image disorders and abuse of anabolic-androgenic steroids among men. JAMA. 2017;317(1):23-24. doi:10.1001/jama.2016.17441 - DOI - PubMed
    1. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality among users of anabolic steroids. JAMA. 2024;331(14):1229-1230. doi:10.1001/jama.2024.3180 - DOI - PMC - PubMed
    1. Rasmussen JJ, Schou M, Madsen PL, et al. . Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. Am Heart J. 2018;203:49-56. doi:10.1016/j.ahj.2018.06.010 - DOI - PubMed
    1. Baggish AL, Weiner RB, Kanayama G, et al. . Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991-2002. doi:10.1161/CIRCULATIONAHA.116.026945 - DOI - PMC - PubMed

Publication types

MeSH terms